Finacea’s generics by Glenmark is an infringe on Bayer AG’s Patent, US court
A US court has recently ruled the decision of proposal of the generic version of Finacea, a skin gel, as an act of infringement by Glenmark Pharmaceuticals. The proposed generic version is currently patented by Bayer AG, a gel for treating the common skin condition rosacea.
The federal court in Wilmington, Delaware is reported to have stressed on the fact that Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent.
Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States
The federal court in Wilmington, Delaware is reported to have stressed on the fact that Glenmark's proposed gel would be absorbed into the skin in a similar way to Finacea, violating Bayer's patent.
Germany's Bayer had sued Glenmark in 2013 after Glenmark filed an application to market a copycat version of the $95 million drug in the United States
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd